欧盟评估虾青素在食品补充剂中作为新型食品的安全性

0
2020-02-11 来源:广东省应对技术性贸易壁垒信息平台

202025日,应欧盟委员会的要求,欧盟食品安全局(EFSA)营养、新型食品和食品过敏原小组(NDA)就虾青素(astaxanthin)在食品补充剂中作为新型食品的安全性发布意见。

经过评估,欧盟NDA小组认为这种虾青素的联合暴露对成人是安全的。

部分原文报道如下:

Following a request from the European Commission, the Panel on Nutrition, Novel Foods and Food Allergens NDA was asked to deliver an opinion on the safety of astaxanthin when used as a novel food in food supplements at maximum levels of 8 mg/day, taking into account the overall cumulative intake of astaxanthin from all food sources. In 2014, the NDA Panel assessed the safety of the novel astaxanthinrich ingredient derived from microalgae Haematococcus pluvialis in the context of an application submitted under Regulation EC No 258/1997. In that opinion, the NDA Panel considered that the acceptable daily intake ADI for astaxanthin was 0.034 mg/kg body weight bw set by the EFSA FEEDAP Panel in 2014. In 2019, the FEEDAP Panel adopted an opinion which concerned the renewal of the authorisation of dimethyldisuccinateastaxanthin and a new use of the additive for crustaceans and other fish than salmonids. In that assessment, the FEEDAP Panel derived a new ADI of 0.2 mg astaxanthin/kg bw which replaced the ADI of 0.034 mg/kg bw established in 2014. By taking into account an updated exposure assessment for astaxanthin from the background diet fish and crustaceans in combination with 8 mg from food supplements, the NDA Panel concludes that i such combined exposure to astaxanthin is safe for adults, ii 14 to < 18 years old adolescents reach the ADI, and iii the ADI is exceeded by 28% in children aged 10 to < 14 years and up to 524% in infants aged 46 months.

相关新闻

版权声明

1、凡本网注明“来源:配资平台配资公司网” 的作品,版权均属于配资平台配资公司网,未经本网授权,任何单位及个人不得转载、摘编或以其它方式使用。已经本网授权使用作品的,应在授权范围内使用,并注明“来源:配资平台配资公司网”。违反上述声明者,本网将追究其相关法律责任。
2、凡本网注明 “来源:XXX(非配资平台配资公司网)” 的作品,均转载自其它媒体,转载目的在于信息之传播,并不代表本网赞同其观点和对其真实性负责。
3、如因作品内容、版权和其它问题需要同本网联系的,请于转载之日起30日内进行。
4、免责声明:本站信息及数据均为非营利用途,转载文章版权归信息来源网站或原作者所有。

返回顶部